The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this 6 month open-label extension trial is to evaluate long-term
safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in
diabetic patients with peripheral arterial occlusive disease (PAOD) and peripheral
neuropathy.